Genmab AS Stock Quote GE9 - Stock Price, News, Charts, Message Board, Trades

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

197.30

Bid

195.50

Ask

197.45

Volume

124

195.35 Day's Range 197.80

191.95 52 Week Range 305.20

Market Cap

12.961B

Previous Close

196.20

Open

196.55

Last Trade

197.3

Last Trade Time

12:26:13

Financial Volume

VWAP

Average Volume (3m)

310

Shares Outstanding

65,691,573

Dividend Yield

PE Ratio

3.16

Earnings Per Share (EPS)

66.25

Revenue

16.47B

Net Profit

4.35B

Sector

Biological Pds,ex Diagnstics

Industry

Biogenetic (human)

Website

www.genmab.com

Headquarters

Copenhagen, Dnk

Founded

2000

Genmab AS is listed in the Biological Pds,ex Diagnstics sector of the Tradegate (DE) with ticker GE9. The last closing price for Genmab AS was 196.20 €. Over the last year, Genmab AS shares have traded in a share price range of 191.95 € to 305.20 €.

Genmab AS currently has 65,691,573 shares outstanding. The market capitalization of Genmab AS is 12.89 € billion. Genmab AS has a price to earnings ratio (PE ratio) of 3.16.

Genmab to Present at Citi’s Global Healthcare Conference

Genmab to Present at Citi’s Global Healthcare Conference Media ReleaseCOPENHAGEN, Denmark; November 25, 2024 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony...

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; November 21, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided...

Genmab Announces Financial Results for the First Nine Months of 2024

Genmab Announces Financial Results for the First Nine Months of 2024 November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2024 Highlights European...

Genmab to Present at Jefferies London Healthcare Conference

Genmab to Present at Jefferies London Healthcare Conference Media ReleaseCOPENHAGEN, Denmark; November 5, 2024 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer, Jan van...

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting Media ReleaseCOPENHAGEN, Denmark; November...

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024 Company Announcement Net sales of DARZALEX® in the third quarter of 2024 totaled USD 3,016 millionGenmab receives...

Major Shareholder Announcement

Major Shareholder Announcement Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; October 4, 2024 – Genmab A/S (Nasdaq: GMAB) announces under reference to...

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; September 26, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided...

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial...

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; September 10, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	2.45	1.25737746985	194.85	200.7	191.95	284	196.72417195	DE
4	-16.5	-7.7174929841	213.8	220.8	191.95	382	205.72247905	DE
12	-53.7	-21.3944223108	251	253.5	191.95	310	214.98863343	DE
26	-60.8	-23.5567609454	258.1	269.5	191.95	258	228.56106715	DE
52	-91.5	-31.6828254848	288.8	305.2	191.95	212	245.00665577	DE
156	-154.9	-43.9806927882	352.2	362.9	191.95	157	251.58008515	DE
260	-176.3	-47.1895074946	373.6	374.3	191.95	155	251.58996865	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
2RZPoseida Therapeutics Inc	8.86 € (224.30%)	44.65k
7S2Scotch Creek Ventures Inc	0.0144 € (67.44%)	100k
ZN80Hesai Group	7.20 € (59.29%)	32.13k
RUOCOcean Power Technologies	0.269 € (56.21%)	685.63k
AXIAtos SE	0.5852 € (55.02%)	2.59M
CHPCitigold Corporation Ltd	0.001 € (-60.00%)	250k
L7C2Windfall Geotek Inc	0.0025 € (-54.55%)	500
0Z2Alector Inc	2.40 € (-36.51%)	5.5k
BDDConico Ltd	0.0004 € (-33.33%)	80k
QN90Military Metals Corp	0.294 € (-32.88%)	282.99k
R1EAEV Resources Ltd	0.002 € (25.00%)	4.8M
D7GNel ASA	0.2708 € (0.67%)	2.85M
AXIAtos SE	0.5852 € (55.02%)	2.59M
PF8European Lithium Limited	0.0172 € (2.38%)	2.43M
3CPXiaomi Corporation	3.307 € (-4.72%)	1.91M